Skip to main content

Learn about cell avidity analysis

Get a better understanding of cell avidity, why is it important and relevant to understand the mechanism of action through the latest publications, webinars, application notes and white papers

Watch our webinars

Explore all

Sarah Tettamanti, PhD Tettamanti Center, Fondazione IRCCS San Gerardo dei Tintori

Cell Avidity Measurements to Understanding the mechanism of action of a novel dual CAR approach with improved efficacy and safety using Cell Avidity

Webinars Marcela Maus

Dr. Marcela Maus, Associate Professor of Medicine Massachusetts General Hospital, Harvard Medical School

Cell Avidity Measurements to Understand and Enhance CAR-T/Tumor Interactions in Acute Myeloid Leukemia

Dr. Rebecca Larson, PhD Graduate from Harvard University

Cell avidity as a crucial biomarker for CAR T response

Webinars Maria Themeli

Dr. Maria Themeli, Group Leader of Hematology Department at Amsterdam UMC Cancer Center Amsterdam

Enhanced avidity through combining a BCMA CAR and a CD38 chimeric co-stimulatory receptor leads to enhanced T cell sensitivity and persistence

Webinars Mark Lowdell

Prof. Mark Lowdell, Professor of Cell & Tissue Therapy at University College London and Chief Scientific Officer of INmune Bio, Inc

Exploring the network of cellular interactions of Natural Killer cells in the tumor microenvironment with cell avidity

Webinars Carlos Fernandez de Larrea

Prof. Carlos Fernandez de Larrea, Associate Professor of Medicine University of Barcelona

Dual-targeted cell therapy targeting BCMA and GPRCD5 to prevent relapse in multiple myeloma

Webinars Will Singleterry

Dr. Will Singleterry, Director of Business Development at LUMICKS

Unveiling a one-to-one relationship of TCR-dependent T cell function and cellular avidity at single-cell level using acoustic force

Read application notes

Explore all

Rapid assessment of CAR T-cell therapy strategies for multiple myeloma with the cell avidity analysis

Prof. Carlos Fernandez de Larrea Associate Professor of Medicine at University of Barcelona

Identify functionally optimal TCR-engineered T cells through cell avidity measurements

Dr. Natalie Rufer Associate Professor at University of Lausanne

Increased cell avidity through CD38 co-receptor drives enhanced BCMA CAR T-cell sensitivity and persistence in multiple myeloma

Dr. Maria Themeli Group Leader of Hematology Department at Amsterdam UMC Cancer Center Amsterdam

Cell avidity measurement: a new accurate method to predict in vivo CAR T cell efficacy and minimize drug discovery timelines

Dr. Marcela Maus Associate Professor at Harvard Medical School and Director of Cellular Immunotherapy at Massachusetts General Hospital

Learn about our technology

How does the z-Movi technology work?

Introducing the acoustic technology within the heart of our z-Movi

The z-Movi workflow

How to perform cell avidity analsis experiments in a mater of hours

What is immunological synapse?

Learn how the formation of an immune synaptic interface between T cells and tumor cells leads to activities required for T cell activation and cytokine release

What is avidity and why is it important?

Understanding the term “cell avidity” and how it fills the current scientific research gap

Want to learn more?

Explore our publications

Read our white papers

Close Menu

For pricing, reach out to your application scientist or account manager

Open Email

Fill in our contact form, we will reach out to you!

Please include ‘Lakeview data analysis price inquiry’ in the Message box

Contact Us


Join our newsletter

Get exclusive news on the latest publications, product developments, events and breakthrough science.

By submitting the form you agree to LUMICKS' privacy policy. You can revoke your consent at any time.

Download our webinar recording:

 

Download our Cell Therapy (CAR-T, TCR, NK) applications deck